 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...910111213141516171819...3839» |
- ||| Lumakras (sotorasib) / Amgen
Just out. Activity of Sotorasib in KRAS G12C-mutated pancreatic adenocarcinoma. One step forward. https://t.co/Mg8C9udg4R (Twitter) - Dec 27, 2022
- |||| Cyramza (ramucirumab) / Eli Lilly, Lumakras (sotorasib) / Amgen, docetaxel / Generic mfg.
Clinical, Real-world evidence, Real-world: That’s not really fair, there’s zero question out here in the real world where we actually treat lung cancer patients all day that Lumakras is at least a thousand percent better in second line G12C than taxotere/cyramza, every doctor and patient would choose Lumakras. (Twitter) - Dec 26, 2022
- || Lumakras (sotorasib) / Amgen
Great thread about our new paper #CodeBreak200 #sotorasib (Twitter) - Dec 26, 2022
- |||| Lumakras (sotorasib) / Amgen
Clinical, Metastases: #PDAC #NEJM 🎯Sotorasib in #KRASG12C #metastaticpancreaaticcancer ✅️38 pts w metastatic disease who received > 2 lines. 👉mPFS 4.0 months 👉mOS 6.9 months ✅️42% treatment-related AEs of any grade ✅️16% grade 3 AEs https://t.co/eyUHniw7u9 📢Target therapy feasible🔥 (Twitter) - Dec 25, 2022
- || Lumakras (sotorasib) / Amgen
Review, Journal: Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital (Pubmed Central) - Dec 25, 2022
Grade 3 acute hepatitis occurred in 3/15 patients (20%). While sotorasib is an interesting therapeutic option, with efficacy that seems better in patients in good general condition, it entails a possible risk of drug-induced hepatitis, which remains to be specified in dedicated studies.
- || Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Review, Journal, IO biomarker: The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy. (Pubmed Central) - Dec 24, 2022
However, due to disease heterogeneity, the prognosis of patients remains unsatisfactory, leaving room for personalized treatment options, such as new targeted therapies and other therapies. In this review, we aim to dissect the strategies of clinical trials in these tumors, shifting from a few chemotherapy options to targeted and immunotherapy, in the context of molecular selection of KRAS-mutant NSCLC subtypes.
- | MRTX1133 / Mirati, Lumakras (sotorasib) / Amgen
Journal: Development of a High-Throughput TR-FRET Screening Assay for a Fast-Cycling KRAS Mutant. (Pubmed Central) - Dec 24, 2022
The most promising hit, UNC10104889, was further investigated through a structure activity relationship (SAR)-by-catalog approach in an attempt to improve potency and circumvent solubility liabilities. Overall, we present the TR-FRET platform as a robust assay to screen fast-cycling KRAS mutants enabling future discovery efforts for novel chemical probes and drug candidates.
- Krazati (adagrasib) / Mirati, Elunate (fruquintinib) / Hutchmed, Lumakras (sotorasib) / Amgen
MODULE 4: Promising Agents and Strategies for Patients with mCRC (San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)) - Dec 23, 2022 - Abstract #ASCOGI2023ASCO_GI_999;
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc. Incidence of KRAS G12C mutations in mCRC; mechanism of action of sotorasib and adagrasib Available efficacy and safety data with sotorasib and adagrasib monotherapy for patients with mCRC and KRAS G12C mutations Rationale for and early data with KRAS-targeted agents in combination with anti-EGFR therapy for mCRC Similarities and differences in the designs and eligibility criteria of the Phase III CodeBreaK 300 and KRYSTAL-10 trials evaluating sotorasib and adagrasib, respectively, in combination with an anti-EGFR antibody for advanced CRC Mechanism of action of fruquintinib; available clinical research data and potential clinical role for patients with R/R mCRC and disease progression on or intolerance to approved standard therapies Other promising agents and strategies under investigation for mCRC
- | Lumakras (sotorasib) / Amgen
Journal, Metastases: Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. (Pubmed Central) - Dec 23, 2022
P1/2
Sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had received previous treatment. (Funded by Amgen and others; CodeBreaK 100 ClinicalTrials.gov number, NCT03600883.).
- ||||| Lumakras (sotorasib) / Amgen
Clinical: At a @CSHL meeting on #PancreaticCancer - 10 years ago…I was told that KRAS would remain undruggable In @NEJM - activity of sotorasib in #pancsm 💜 ✅ 38 heavily pretreated #cancer #patients ✅ ORR 21% ✅ PFS 4 months ✅ OS 6.9 months @OncoAlert 🚨 https://t.co/jAFwWt2VUi (Twitter) - Dec 23, 2022
- |||| Lumakras (sotorasib) / Amgen
Clinical, Metastases: Sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C–mutated advanced pancreatic cancer who had received previous treatment @oncologician @SewantiLimaye https://t.co/LXLFphkRxG (Twitter) - Dec 23, 2022
- |||| Lumakras (sotorasib) / Amgen
Clinical, P1/2 data, Metastases: UF Health was a study location for this phase 1-2 trial involving sotorasib treatment for patients with KRAS G12C-mutated advanced #PancreaticCancer. Congrats to coauthor @TGeorgeMD and colleagues! #PrecisionOncology #Oncology #CancerResearch Read more👇 (Twitter) - Dec 22, 2022
- |||| Lumakras (sotorasib) / Amgen
Metastases: "Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer." Publié ce jour dans le @NEJM. Un peu d'espoir à l'horizon? #MedTwitter #GITwitter @Beaudoinannie2 @dradesnoyers @MaxCPoirier @tehfem https://t.co/DXvAq6Z5Dj (Twitter) - Dec 22, 2022
- |||| Lumakras (sotorasib) / Amgen
Metastases: Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM https://t.co/5GySfYoLm9 (Twitter) - Dec 22, 2022
- ||||| Krazati (adagrasib) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lumakras (sotorasib) / Amgen
Metastases: Hitting the undruggable targets in pancreatic and colorectal cancers! 🧬Sotorasib in KRAS p.G12C–Mutated Advanced #Pancreatic #Cancer 🧬Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C @NEJM @MSKCancerCenter @MDAndersonNews @RonaYaeger @OncoAlert (Twitter) - Dec 22, 2022
- |||| Lumakras (sotorasib) / Amgen
Clinical: The RAS mutation has been seen as an insurmountable target for 40 years. It has finally become targetable. We are just at the beginning of the road. We have a long road ahead of us, but the results are promising. Efficacy of sotorasib in pancreatic cancer👇 (Twitter) - Dec 21, 2022
- ||||| Lumakras (sotorasib) / Amgen
Clinical: 🔥Sotorasib in KRAS p.G12C mutant #PDAC @NEJM https://t.co/8hzjb183n3 ✅38pts, CodeBreaK 100 👉ORR: 21%, worse than NSCLC, better than CRC 👉mPFS 4 mo, mOS 6.9 mo 👉Meaningful efficacy & acceptable safety 😀The first step to make the un-draggable🎯 druggable @myESMO @OncoAlert (Twitter) - Dec 21, 2022
- || Lumakras (sotorasib) / Amgen
5-Pankreas kanseri teşhis ve tedavisi en zor kanserlerden biridir. Bu faz 1-2 denemesinde, sotorasib monoterapisi, önceden yoğun şekilde tedavi edilmiş KRAS p.G12C mutasyonlu ilerlemiş pankreas kanseri olan hastalarda umut verici antikanser aktivite gösterdi. (Twitter) - Dec 21, 2022
- ||| Lumakras (sotorasib) / Amgen
2-Bu çalışma, KRAS p.G12C mutasyonlu pankreas kanseri olan hastalarda sotorasib adlı KRAS G12C inhibitörü ilacın etkinliğini ve güvenliğini değerlendirmek için uluslararası, çok merkezli faz 1-2 çalışmasıdır. (Twitter) - Dec 21, 2022
- |||| Lumakras (sotorasib) / Amgen
Metastases: Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM https://t.co/V2kObJZSrN (Twitter) - Dec 21, 2022
- |||| Lumakras (sotorasib) / Amgen
Metastases: Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM https://t.co/ecoAILngsJ (Twitter) - Dec 21, 2022
- ||| Lumakras (sotorasib) / Amgen, docetaxel / Generic mfg.
Clinical: I agree, there was no OS difference in CodeBreak 200 trial. However, it should not be forgotten that one third of the patients in the docetaxel arm subsequently received sotorasib. Also, the study was not powered for OS. (Twitter) - Dec 20, 2022
- || Krazati (adagrasib) / Mirati, MRTX1133 / Mirati, Lumakras (sotorasib) / Amgen
Review, Journal, IO biomarker: KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? (Pubmed Central) - Dec 20, 2022
Exciting advances in this field also include an immunotherapeutic approach that uses adoptive T-cell transfer to specifically target G12D in pancreatic cancer. In this mini-review, we discuss recent advances in KRAS G12D targeting and the potential for further clinical development of the various approaches.
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Dec 20, 2022
P1b/2, N=1143, Recruiting, Sponsor: Amgen
In this mini-review, we discuss recent advances in KRAS G12D targeting and the potential for further clinical development of the various approaches. Trial completion date: Oct 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Dec 2024
- ||||| Lumakras (sotorasib) / Amgen
11) ❓Role of #KRASG12C + #immunotherapy? @IASLC #WCLC22 #Sotorasib w/#IO Dr. Li @MSKCancerCenter presented CodeBreak 100/101 🛑G3>= TRAEs: 50-74% (concurrent), 2 grade 5‼️ ➡️ORR: 29% @KRASKickers #LCSM (Twitter) - Dec 15, 2022
- Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Incidence and prognosis of KRAS subtypes and co-mutations in non-small metastatic cell cancer: retrospective study at the CAEN CHU between 2016 and 2020 (Display area) - Dec 14, 2022 - Abstract #CPLF2023CPLF_792;
The emergence of specific Kras G12C treatments in the second line (Sotorasib, Adagrasib) and the development of specific treatments outside G12C or Pan-Kras could improve the survival of Kras mutated patients. The prognosis impact and the therapeutic involvement of KRAS co -mutations remain to be specified.
- Avastin (bevacizumab) / Roche, Lumakras (sotorasib) / Amgen
First real life data of patients (PTS) with bronchial cancer non -small metastatic cells (CBNPCM) mutated Krasg12c within the French temporary authorization program (ATU): clinical characteristics of 679 pts at the Treatment initiation (Display area) - Dec 14, 2022 - Abstract #CPLF2023CPLF_302;
P=N/A
DY GK, et al. Presented at American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022; New Orleans, La.
- Lumakras (sotorasib) / Amgen
Treatment with Sotorasib in early access authorization in pulmonary cancer not with small mutated cells Kras G12C: experience of the Tours CHRU (Display area) - Dec 14, 2022 - Abstract #CPLF2023CPLF_301;
The occurrence of grade 3 acute hepatitis was found in 3/15 patients (20%), with a risk that could be increased in the event of previous treatment by immunotherapy targeting the PD-1 path. Conclusion Sotorasib is an interesting therapeutic option, with an efficiency that seems better in patients with good general condition, but a possible risk of drug hepatitis, which remains to be specified by dedicated studies.
- Lumakras (sotorasib) / Amgen
Evaluation of the resistance acquired for sotorasib in colorectal cancer (CCR) and bronchial cancer not with small cells (CBNPC) with Kras G12C mutation: analysis of plasma biomarkers of the Codebreak 100 study (Display area) - Dec 14, 2022 - Abstract #CPLF2023CPLF_297;
P1/2
Information on clinical study: NCT03600883. Study promoter: Amgen Inc.
- |||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Clinical: As new drugs for #KRAS-altered lung cancer become available, "it's very much a 'dealer's choice' whether clinicians choose" sotorasib, with "rather underwhelming" reported results, or the "less defined possibility" of adagrasib, @JackWestMD https://t.co/E2umuY0ocW? @OBRTweets (Twitter) - Dec 14, 2022
- |||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Clinical: Just in time for the holidays #adagrasib approved for #KRASG12c #lungcancer. Second targeted therapy approved for this common mutation found in 13% (1 in 8 cases) ➡️ Based on KRYSTAL-1 trial OR 43% DCR 80% ➡️Competes w sotorasib w diff toxicity profile #lcsm @KRASKickers (Twitter) - Dec 13, 2022
- ||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Clinical: Definitely interesting to see that KRYSTAL7 (ICI/Adagrasib) data looks better than ICI/Sotorasib- this space is 🔥, 🗝️ developments for our patients!! @KRASKickers 🙏🏻 (Twitter) - Dec 13, 2022
- ||||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Clinical, FDA event: 🚨Adagrasib was granted accelerated #FDA approval for pts with #NSCLC & #KRAS G12C mutation after 1 line of treatment based on #KRYASTAL-1: ➡️600mg twice daily ➡️ORR 43% ➡️mDOR 8.5, mPFS 6.5 mo ➡️IC ORR 33% ➡️TRAEs 97.4%! ❓Adagrasib vs Sotorasib #LCSM @OncoAlert @HemOncFellows (Twitter) - Dec 13, 2022
- |||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Clinical: From a 1st hand experience as a lowly co-investigator♟️, I can tell you the times these pts were on these 💊, #sotoRASib or #adagRASib, QOL📈. All recalled how this was so much better than chemo. Best story:☝🏽pt biked🚴 to clinic for scans, was on oxygen before.🙌🏾 #KRASG12C https://t.co/vLHdRFHlLt (Twitter) - Dec 13, 2022
- ||||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Accelerated approval by @US_FDA for KRAZATI (@Mirati Adagrasib) in locally advanced or metastatic #LungCancer with KRAS G12C mutation. And then there were two (KRAZATI & LUMAKRAS). https://t.co/GI6T8Z65aJ (Twitter) - Dec 12, 2022
- ||| Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen, docetaxel / Generic mfg.
Clinical, Monotherapy: I'm underwhelmed by sotorasib's failure to beat docetaxel monotherapy for OS. Should we favor adagrasib, with perhaps better efficacy but toxicity issues that are real concerns? I think we have to wait for rand ph 3 of adagrasib vs. doce; until then, dealer's choice, IMO. (Twitter) - Dec 12, 2022
- ||| Lumakras (sotorasib) / Amgen
Aadagrasib approved in NSCLC, 11% grade 5 AEs. Thoughts? Preference vs sotorasib? @jessicajlinmd @fernandoonco @MLJohnsonMD2 @CParkMD @VivekSubbiah @LealTiciana @jgong15 @VPrasadMDMPH @StephenVLiu @JackWestMD @drgandara @jsoriamd @vanitanoronha @harpreet_md @drjnaidoo #lcsm (Twitter) - Dec 12, 2022
- |||| adagrasib (MRTX849) / Mirati, Lumakras (sotorasib) / Amgen
Clinical, FDA event: 🔥🚨Hot off the press @US_FDA approves #Adagrasib for patients with #KRAS-#G12C mutant advanced non-small cell #LungCancer Based on #KRYSTAL-1 study: ORR: 43% mDOR: 8.5 months This’s 2nd approved KRAS drug after #Sotorasib @OncoAlert @KRASKickers #LCSM https://t.co/ZZF4oHl6tw (Twitter) - Dec 12, 2022
- |||| adagrasib (MRTX849) / Mirati, Lumakras (sotorasib) / Amgen
Clinical, FDA event: 🚨 It's just Monday & we have another #precisionmedicine FDA approved !!! 🎯🧬🫁 #LCSM 📢 ADAGRASIB is now FDA approved for KRAS G12C #lungcancer Brand name is "Krazati" KRAS G12C patients have 2 options- Sotorasib & now this. https://t.co/WoZfyGGJGY (Twitter) - Dec 12, 2022
- |||| adagrasib (MRTX849) / Mirati, Lumakras (sotorasib) / Amgen
FDA event: Adagrasib (Krazati) receives FDA accelerated approval for previously treated #KRAS G12C NSCLC joining sotorasib as a targeted therapy option for this relatively common genomic subset of lung cancer. #LCSM https://t.co/lHLjlBJl9q (Twitter) - Dec 12, 2022
- || adagrasib (MRTX849) / Mirati, Lumakras (sotorasib) / Amgen
Review, Journal: Non-genetic adaptive resistance to KRAS inhibition: EMT is not the only culprit. (Pubmed Central) - Dec 10, 2022
Deciphering and targeting cancer adaptions promises mechanistic insights into tumor pathobiology and improved clinical management of KRAS-mutant cancer. This review presents recent advances in non-genetic adaptations leading to resistance to KRAS inhibitors, with a focus on oncogenic pathway rewiring, TME, and EMT.
- || Lumakras (sotorasib) / Amgen
Liver tox from Lumakras takes on average more than a month to surface( 5-6 week). (Twitter) - Dec 8, 2022
- || adagrasib (MRTX849) / Mirati, Keytruda (pembrolizumab) / Merck (MSD), Lumakras (sotorasib) / Amgen
Less toxicity for the combination of pembro with adagrasib compared with combination with sotorasib. Different drugs? Or wrong dose of sotorasib? Happy to have this trial at @UChicagoHemOnc (Twitter) - Dec 8, 2022
- ||| Lumakras (sotorasib) / Amgen
Clinical: Any thoughts on the following: 1. TRAE D/C really diff. 50% in concurrent Soto/IO vs 6% Ada/IO- but 1L vs 2L setting so patient pop/tolerability diff? Sotorasib had previous IO- ⬆️ hepatotox 2. Sotorasib/IO (2L)-30% ORR vs Ada/IO (1L)-49%- really only additive? ~Chemo/IO 1L? (Twitter) - Dec 7, 2022
- || Lumakras (sotorasib) / Amgen
Watch: #ProjectLivinLabel on sotorasib. #NSCLC #OCEProjectSocrates (Twitter) - Dec 7, 2022
- ||||| Clinical, Real-world evidence, Circulating tumor DNA: @myESMO #ESMOImmuno22 🔥proferred #LCSM session! ➡️ Adagrasib/Pembro, ⬇️ A/E then sotorasib #WCLC22! ➡️ PACIFIC-R @nicogirardcurie, #Durva ⬆️ OS in Real World ➡️ PD1 Wars: Dostarlimab ~ Pembro 1L mNSCLC with chemo! @peters_solange ➡️ IMPower010 ctDNA analysis @EnriquetaFelip (Twitter) - Dec 7, 2022
- ||| Lumakras (sotorasib) / Amgen
Adverse events: Personal thought Before we jump and accept that this combo doesnt inc grade 3 side effect we should do a larger trial and see i worry since we saw the toxicity with I/O + Sotorasib maybe it is not a class effect but the burden of proof should fall on the drug comapny and us (Twitter) - Dec 7, 2022
- | Lumakras (sotorasib) / Amgen
Journal: Validation of an LC-MS/MS method for the determination of sotorasib, a KRAS inhibitor, in human plasma. (Pubmed Central) - Dec 7, 2022
Stable isotope labeled [C, D]-sotorasib was used as an internal standard. Results and The method fully met FDA guidelines for all validation parameters, including precision, accuracy, selectivity, matrix effect, recovery and stability and has been extensively used to support multiple clinical studies.
- |||| Lumakras (sotorasib) / Amgen
If I am@not mistaken the I/o combination with Sotorasib ( Amgen product ) showed very high rates of liver toxicity (Twitter) - Dec 7, 2022